Compounds > n-(((4-benzoylamino)phenyl)sulfonyl)glycine
Page last updated: 2024-12-07

n-(((4-benzoylamino)phenyl)sulfonyl)glycine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(((4-benzoylamino)phenyl)sulfonyl)glycine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID130998
CHEMBL ID37092
SCHEMBL ID4834530
MeSH IDM0173180

Synonyms (13)

Synonym
n-((4-(benzoylamino)phenyl)sulfonyl)glycine
n-(((4-benzoylamino)phenyl)sulfonyl)glycine
glycine, n-((4-(benzoylamino)phenyl)sulfonyl)-
109065-69-2
bapsg
CHEMBL37092 ,
(4-benzoylamino-benzenesulfonylamino)-acetic acid
bdbm50016550
2-[(4-benzamidophenyl)sulfonylamino]acetic acid
SCHEMBL4834530
n-[[4-(benzoylamino)phenyl] sulfonyl]glycine
n-(4-benzamidobenzene-1-sulfonyl)glycine
DTXSID30910981

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" In the topical dosing study, a significant decline in BAPSG delivery was observed in the iris-ciliary body but no significant changes were observed in other tissues of the anterior segment of the eye including tears."( Probenecid treatment enhances retinal and brain delivery of N-4-benzoylaminophenylsulfonylglycine: an anionic aldose reductase inhibitor.
Ayalasomayajula, SP; DeRuiter, J; Kompella, UB; Sunkara, G, 2010)		0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)0.64500.00041.877310.0000AID34802; AID34970
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID34970Inhibitory concentration against aldose reductase obtained from rat lens1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
N- and 2-substituted N-(phenylsulfonyl)glycines as inhibitors of rat lens aldose reductase.
AID34802Inhibition of rat aldose reductase enzyme.1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Novel inhibitors of rat lens aldose reductase: N-[[(substituted amino)phenyl]sulfonyl]glycines.
AID34984Inhibition of rat aldose reductase activity at 100 uM.1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Novel inhibitors of rat lens aldose reductase: N-[[(substituted amino)phenyl]sulfonyl]glycines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (33.33)18.7374
1990's1 (11.11)18.2507
2000's4 (44.44)29.6817
2010's1 (11.11)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.18 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
glycine
[no description available]		3.3870alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
probenecid
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.		2.0510benzoic acids;
sulfonamide		uricosuric drug
thiazoles
[no description available]		2101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
fluorescein
Fluorescein: A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium such as the aqueous humor.. fluorescein (lactone form) : A xanthene dye that is highly fluorescent, detectable even when present in minute quantities. Used forensically to detect traces of blood, in analytical chemistry as an indicator in silver nitrate titrations and in microscopy.		2102-benzofurans;
gamma-lactone;
organic heteropentacyclic compound;
oxaspiro compound;
polyphenol;
xanthene dye		fluorescent dye;
radioopaque medium
thiazolyl blue
thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.		210organic bromide saltcolorimetric reagent;
dye
n-4-tosylglycine
N-4-tosylglycine: facilitates insulin release		1.9710
n-(phenylsulfonyl)glycine
[no description available]		1.9710
sorbinil
sorbinil: aldose reductase inhibitor. sorbinil : An azaspiro compound having a monofluoro-substituted chromane skeleton spiro-linked to an imidazolidinedione ring.		2.3720azaspiro compound;
chromanes;
imidazolidinone;
organofluorine compound;
oxaspiro compound		antioxidant;
EC 1.1.1.21 (aldehyde reductase) inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Alloxan Diabetes
[description not available]		02.0110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0110